Hopwood S E, Stamford J A
Neurotransmission Laboratory, Academic Department of Anaesthesia and Intensive Care, St Bartholomew's and The Royal London School of Medicine and Dentistry, Alexandra Wing, Royal London Hospital, Whitechapel, London E1 1BB, UK.
Neuropharmacology. 2001 Sep;41(4):433-42. doi: 10.1016/s0028-3908(01)00087-9.
The rat rostral raphé nuclei receive catecholaminergic innervation from the locus coeruleus and other areas. In the present study, we investigated noradrenergic modulation of 5-HT release in rat dorsal and median raphé nuclei (DRN and MRN) slices (350 microm thick) superfused with artificial cerebrospinal fluid (aCSF). The raphé was locally stimulated (0.1 ms pulses, 10 mA) and 5-HT release was monitored at carbon fibre microelectrodes using fast cyclic voltammetry. The selective noradrenaline reuptake inhibitor desipramine (50 nM) did not increase stimulated (20 pulses, 100 Hz) 5-HT release but significantly slowed 5-HT reuptake in both DRN and MRN. On short stimulus trains (10 pulses, 200 Hz), the alpha(2)-selective agonist dexmedetomidine (10nM) decreased evoked 5-HT release in DRN and MRN (to 44+/-3 and 43+/-7% of pre-drug values, respectively, at minimum). In both nuclei, this response was antagonised by the selective alpha(2A)-antagonist BRL 44408 (1 microM: P<0.001 vs. dexmedetomidine) but not by the selective alpha(2B/C)-adrenoceptor antagonist ARC 239 (500 nM), the selective 5-HT(1A) antagonist WAY 100635 (100 nM) or the alpha(1)-selective antagonist prazosin (1 microM), suggesting that the effect of dexmedetomidine is wholly attributable to alpha(2A)-receptor activation. The alpha(1)-adrenoceptor agonist phenylephrine (5 microM) significantly decreased 5-HT release (to 49+/-7 and 41+/-4% of pre-drug values in DRN and MRN, respectively). The response was blocked by prazosin (P<0.001) and BRL 44408 (P<0.01) in DRN and by prazosin, BRL 44408 and WAY 100635 (all P<0.05) in MRN, suggesting that the effect of phenylephrine is, under these conditions, only partly mediated via alpha(1)-adrenoceptors. On long stimuli (30 pulses, 10 Hz), BRL 44408 (1 microM) increased evoked 5-HT efflux to 187+/-17 and 178+/-2% of pre-drug values in DRN and MRN, respectively (both P<0.001 vs. vehicle). Collectively, these data show that activation of both alpha(1) and alpha(2A)-adrenoceptors can decrease stimulated 5-HT release in the rostral raphé nuclei. Since the effect of dexmedetomidine was not antagonised by prazosin, we suggest that its effect was mediated directly, possibly through alpha(2A) receptors located on 5-HT cell elements, and not transduced indirectly through alpha(1)-adrenoceptor activation, as previously suggested by others.
大鼠吻侧中缝核接受来自蓝斑及其他区域的儿茶酚胺能神经支配。在本研究中,我们研究了在灌流人工脑脊液(aCSF)的大鼠背侧和中缝核(DRN和MRN)薄片(350微米厚)中去甲肾上腺素能对5-羟色胺(5-HT)释放的调节作用。对中缝核进行局部刺激(0.1毫秒脉冲,10毫安),并使用快速循环伏安法在碳纤维微电极上监测5-HT的释放。选择性去甲肾上腺素再摄取抑制剂地昔帕明(50纳摩尔)并未增加刺激(20个脉冲,100赫兹)引起的5-HT释放,但显著减慢了DRN和MRN中5-HT的再摄取。在短刺激序列(10个脉冲,200赫兹)时,α₂选择性激动剂右美托咪定(10纳摩尔)降低了DRN和MRN中诱发的5-HT释放(最低分别降至给药前值的44±3%和43±7%)。在两个核中,该反应被选择性α₂A拮抗剂BRL 44408(1微摩尔:与右美托咪定相比,P<0.001)拮抗,但未被选择性α₂B/C肾上腺素能受体拮抗剂ARC 239(500纳摩尔)、选择性5-HT₁A拮抗剂WAY 100635(100纳摩尔)或α₁选择性拮抗剂哌唑嗪(1微摩尔)拮抗,这表明右美托咪定的作用完全归因于α₂A受体激活。α₁肾上腺素能受体激动剂去氧肾上腺素(5微摩尔)显著降低了5-HT释放(DRN和MRN中分别降至给药前值的49±7%和41±4%)。在DRN中,该反应被哌唑嗪(P<0.001)和BRL 44408(P<0.01)阻断,在MRN中被哌唑嗪、BRL 44408和WAY 100635(均P<0.05)阻断,这表明在这些条件下,去氧肾上腺素的作用仅部分通过α₁肾上腺素能受体介导。在长刺激(30个脉冲,10赫兹)时,BRL 44408(1微摩尔)使DRN和MRN中诱发的5-HT流出分别增加至给药前值的187±17%和178±2%(与溶剂相比,均P<0.001)。总体而言,这些数据表明α₁和α₂A肾上腺素能受体的激活均可降低吻侧中缝核中刺激引起的5-HT释放。由于右美托咪定的作用未被哌唑嗪拮抗,我们认为其作用是直接介导的,可能通过位于5-HT细胞成分上的α₂A受体,而不是如其他人之前所提出的通过α₁肾上腺素能受体激活间接传导。